Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Inspire Medical Systems ( (INSP) ) just unveiled an announcement.
Inspire Medical Systems reported on February 11, 2026 that it ended 2025 with solid momentum, driven by the full commercial launch of its Inspire V system, 12% fourth-quarter revenue growth to $269.1 million and 14% full-year revenue growth to $912.0 million, alongside rising gross margins and a swing to strong profitability supported by an $85.8 million fourth-quarter tax benefit. The company generated $117.0 million in full-year operating cash flow, repurchased $175 million of stock and guided 2026 revenue to $950 million–$1.0 billion with adjusted operating margin of 6%–8%, while acknowledging reimbursement headwinds from a coding clarification that shifts Inspire V procedures to CPT code 64582 with a -52 modifier, and separately moved to enhance shareholder governance by proposing board declassification and director removal rules aligned with Delaware law for a 2026 stockholder vote.
In preparation for this governance change, the board on February 5, 2026 approved amended bylaws, contingent on stockholder approval, that would eliminate the “for cause only” removal restriction and instead rely on the updated charter provisions. The company also disclosed plans to meet investors and analysts in February and March 2026 using a new investor presentation, underscoring management’s effort to communicate both the growth opportunity and reimbursement and margin dynamics as it seeks to sustain long-term profitable expansion and shareholder value creation.
The most recent analyst rating on (INSP) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Spark’s Take on INSP Stock
According to Spark, TipRanks’ AI Analyst, INSP is a Neutral.
INSP’s score is driven primarily by strong financial fundamentals (high margins, improving profitability, low leverage) and a solid fundamental outlook from guidance and recent business updates. These positives are meaningfully offset by weak technicals (below key moving averages with negative MACD) and a high P/E valuation with no dividend support.
To see Spark’s full report on INSP stock, click here.
More about Inspire Medical Systems
Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea. Its proprietary Inspire therapy is the first neurostimulation technology approved by the FDA, EU MDR and Japan’s PDMA for treating moderate to severe obstructive sleep apnea, positioning the firm in a specialized, high‑growth segment of the sleep-disorder market.
Average Trading Volume: 1,582,964
Technical Sentiment Signal: Sell
Current Market Cap: $1.93B
For detailed information about INSP stock, go to TipRanks’ Stock Analysis page.